SCHEMBL13640

SCHEMBL13640

CCOC(=O)C(C)(C)c1ccc(-c2ccc(-c3onc(C)c3Nc3cccc(-c4ccccc4)n3)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 4/20 0.39
LPAR3 Q9UBY5 2/20 0.39
MAPT P10636 4/20 0.38
KDM4E B2RXH2 1/20 0.38
ADORA3 P0DMS8 1/20 0.37
LPAR2 Q9HBW0 1/20 0.36
ABCC3 O15438 1/20 0.35
ABCC4 O15439 1/20 0.35
ABCB11 O95342 1/20 0.35
CYP2C8 P10632 1/20 0.35
CYP2C9 P11712 1/20 0.35
ABCB4 P21439 1/20 0.35
ABCC2 Q92887 1/20 0.35
SLCO1B3 Q9NPD5 1/20 0.35
SLCO1B1 Q9Y6L6 1/20 0.35
CNR2 P34972 1/20 0.34
DHODH Q02127 1/20 0.34
P2RY12 Q9H244 1/20 0.34
ATM Q13315 1/20 0.34
TARBP2 Q15633 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4316 0.89 MAPT (0.41) LPAR1LPAR3MAPTKDM4EADORA3
SCHEMBL5388 0.83 LPAR1 (0.47) LPAR1LPAR3MAPTKDM4ELPAR2
SCHEMBL5049 0.82 LPAR1 (0.42) LPAR1LPAR3MAPTKDM4ELPAR2
SCHEMBL4180 0.80 LPAR1 (0.49) LPAR1LPAR3MAPTABCC3ABCC4
SCHEMBL10083 0.80 LPAR1 (0.56) LPAR1LPAR3MAPTKDM4ELPAR2
SCHEMBL4548 0.80 LPAR1 (0.46) LPAR1LPAR3MAPTABCC3ABCC4
SCHEMBL4392 0.79 LPAR1 (0.42) LPAR1LPAR3MAPTKDM4EADORA3
SCHEMBL4137 0.78 FFAR1 (0.46) LPAR1LPAR3MAPTKDM4ELPAR2
SCHEMBL4489 0.76 LPAR1 (0.44) LPAR1LPAR3MAPTKDM4ELPAR2
SCHEMBL4576 0.76 LPAR1 (0.58) LPAR1LPAR3MAPTKDM4EADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2483251-B1 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS INC (US) 2016-10-26 EP disclosed
EP-2483251-B1 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS INC (US) 2016-10-26 EP disclosed
US-8664220-B2 Polycyclic compounds as lysophosphatidic acid receptor antagonists AMIRA PHARMACEUTICALS, INC. (US) 2014-03-04 US disclosed
US-8664220-B2 Polycyclic compounds as lysophosphatidic acid receptor antagonists AMIRA PHARMACEUTICALS, INC. (US) 2014-03-04 US disclosed
US-20130072490-A1 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS INC. (US) 2013-03-21 US disclosed
US-20130072490-A1 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS INC. (US) 2013-03-21 US disclosed
WO-2011041462-A2 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS, INC. (US) 2011-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072490-A1 POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 5/4885MAPT 4435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.